Oppenheimer & Co. Inc. Strengthens Equities and Biotech Research Teams with Addition of Kostas Biliouris, Ph.D.
Rhea-AI Summary
Oppenheimer (NYSE: OPY) announced on Dec. 8, 2025 that Kostas Biliouris, Ph.D., joined as Managing Director on its Biotech Research Team, based in New York and reporting to William Bird.
Biliouris previously worked at BMO Capital Markets covering genetic medicines, was a VP in biotech research at Morgan Stanley, and held drug development and product strategy roles at Novartis. His background includes a Ph.D. in biochemical engineering and scientific publications with Biogen, Ionis, Merck, Novartis, and the FDA. The firm said the hire strengthens Oppenheimer's long-standing healthcare and biotech research franchise and expands coverage across genetic medicines and related sectors.
Positive
- None.
Negative
- None.
Market Reality Check
Peers on Argus 1 Up
Sector peers show mixed moves, with HIVE down 5.02%, BTBT down 5.13%, and others like SWIN up 3.8%. Momentum scanner only flags CANG up 8.26% with no news, suggesting this Oppenheimer biotech-research hire is more company-specific than part of a broad sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 17 | Leadership appointment | Positive | -4.1% | Appointed Keith Peterson as Head of Cash Equity Sales and Trading. |
| Oct 31 | Quarterly earnings | Neutral | +0.7% | Reported Q3 2025 results with higher revenue but lower EPS year over year. |
| Oct 29 | Leadership appointment | Positive | -1.4% | Hired Guy T. Logan as MD, Head of Infrastructure & Mid-Atlantic Region. |
| Oct 06 | Leadership appointment | Positive | +0.2% | Named James Yoo MD in Healthcare Equity Capital Markets Investment Banking. |
| Sep 30 | Platform expansion | Positive | -2.6% | Expanded CAPS to a comprehensive multi-asset custody and prime platform. |
Recent strategic and personnel announcements have often seen muted or negative next-day price reactions, even when the news highlights platform expansion or senior hires.
Over the last few months, Oppenheimer has focused on expanding key franchises and leadership depth. Hires such as heads of Cash Equity Sales and Trading and Public Finance, plus a Managing Director for Healthcare Equity Capital Markets, underscore efforts to grow equities, healthcare, and public finance capabilities. Platform initiatives like the CAPS expansion and solid Q3 2025 revenue growth to $424.4M frame today’s biotech research team hire as another step in broadening its healthcare and capital markets footprint.
Market Pulse Summary
This announcement adds a senior biotech-focused Managing Director to Oppenheimer’s research team, reinforcing one of its longest-standing healthcare franchises. It follows earlier moves to strengthen healthcare equity capital markets and expand platforms like CAPS. Investors may track how expanded biotech coverage and relationships influence capital markets activity and advisory revenue, while also monitoring expense trends and the contribution of healthcare-related initiatives to overall results.
AI-generated analysis. Not financial advice.
The addition of well-respected biotech expert strengthens one of Oppenheimer's longest-standing franchise areas
Biliouris comes to Oppenheimer from BMO Capital Markets, where he was a Director, mainly covering the genetic medicines space. Before BMO, he was a VP in Biotech Research at Morgan Stanley and worked in drug development and product strategy at Novartis. His background includes a Ph.D. in biochemical engineering and his scientific work was published in collaboration with Biogen, Ionis, Merck, Novartis, and the FDA.
"Kostas brings a rare combination of scientific depth, industry experience, and securities analysis that fits directly into our approach to biotech equity research," Bird said. "His commercial mindset has been shaped by years of engagement with investors and corporate leaders, making him highly regarded by institutional and corporate clients. We are excited to expand Oppenheimer's research coverage of biotech, an area of rapid innovation and increasing focus for our clients. Kostas brings extraordinary experience and perspective and we are thrilled to have him onboard."
Oppenheimer provides coverage across the healthcare ecosystem, including biotechnology, pharmaceuticals, medical technology, and related sectors. The healthcare franchise has long been one of the firm's most established areas of expertise.
"I am excited to join Oppenheimer's research team and contribute to a platform known for its commitment to Healthcare and thoughtful industry coverage," Biliouris said. "The pace of innovation in genetic medicines and the broader biotech space continues to accelerate, and I look forward to working with colleagues to help make sense of these developments for the firm's clients."
About Oppenheimer Holdings Inc.
Oppenheimer Holdings Inc., through its Oppenheimer & Co. Inc. subsidiary, and related entities, provides a full range of wealth management, securities brokerage, and investment banking services to high-net-worth individuals, families, corporate executives, businesses, and institutions. For more information, please visit www.oppenheimer.com.
Media Contact:
Michael Dugan
Haven Tower Group LLC
424 317 4852
mdugan@haventower.com
View original content:https://www.prnewswire.com/news-releases/oppenheimer--co-inc-strengthens-equities-and-biotech-research-teams-with-addition-of-kostas-biliouris-phd-302632809.html
SOURCE Oppenheimer & Co. Inc.
FAQ
Who is Kostas Biliouris and what role did he join at Oppenheimer (OPY) on Dec. 8, 2025?
What is Kostas Biliouris's experience relevant to Oppenheimer's biotech coverage (OPY)?
How does the December 8, 2025 hire affect Oppenheimer's (OPY) healthcare research coverage?
Will Kostas Biliouris's research at Oppenheimer (OPY) focus on genetic medicines?
Who will Kostas Biliouris report to at Oppenheimer (OPY) and where is he based?
How can investors follow Oppenheimer's (OPY) expanded biotech research after the hire?
